April 2, 2018 10:34 AM EDT

AstraZeneca hands Compugen $10M to launch I/O discovery deal; RA Capital joins opposition to proposed BioCryst/Idera merger

John Carroll

Editor & Founder

→ Israel’s Compugen $CGEN nabbed a $10 million upfront to get started on a discovery deal with AstraZeneca on bi- and multi-specific antibodies for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca hands Compugen $10M to launch I/O discovery deal; RA Capital joins opposition to proposed BioCryst/Idera merger

John Carroll

Editor & Founder

Sign up to read this article for free.

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

CagriSema’s weight loss data disappointed. What does Novo do next?

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

As­traZeneca hands Com­pu­gen $10M to launch I/O dis­cov­ery deal; RA Cap­i­tal joins op­po­si­tion to pro­posed BioCryst/Idera merg­er

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

AstraZeneca hands Compugen $10M to launch I/O discovery deal; RA Capital joins opposition to proposed BioCryst/Idera merger

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CMS explains what went into its first round of drug price negotiations

CagriSema’s weight loss data disappointed. What does Novo do next?

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US